Christina A Brezing1,2, C Jean Choi3, Martina Pavlicova4, Daniel Brooks1, Amy L Mahony1, John J Mariani1,2, Frances R Levin1,2. 1. Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York. 2. Department of Psychiatry, Columbia University Medical Center, New York, New York. 3. Division of Biostatistics, New York State Psychiatric Institute, New York, New York. 4. Department of Biostatistics, Columbia University, New York, New York.
Abstract
BACKGROUND AND OBJECTIVE: Many patients with cannabis use disorder (CUD) do not achieve or do not have abstinence as a goal of treatment, rather they reduce their use. Assessing outcome measures as they relate to functioning and reductions in cannabis use is an important area of study. Quality of life (QoL) shows promise as one such measure. Past studies have demonstrated gender differences in QoL and CUD. We aim to assess (1) the relationship between cannabis use and QoL and (2) gender effects in an outpatient medication treatment study for CUD. METHODS: Data from an 11-weeks, double-blind, placebo-controlled trial of lofexidine and dronabinol for CUD (n = 62) was analyzed. Pearson's correlations between baseline QoL as measured with the Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form (QLES-Q-SF) and cannabis use assessed with modified timeline follow-back (TLFB) were examined. Multiple linear regression models of cannabis use on end of study QLES-Q-SF were analyzed, while adjusting for baseline QLES-Q-SF, study arm, and gender. Moderation effects with gender were also tested. RESULTS: No significant association between baseline cannabis use and QoL was found. End of study abstinence (F1,47 = 8.34, p = .006) and reduced proportion of using days (F1,47 = 9.48, p = .004) were each significantly associated with end of study QoL. Reduction in grams (F1,27 = 0.25, p = .62) was not associated with QoL at end of study. Gender was not a significant moderator. DISCUSSION AND CONCLUSIONS: Abstinence and lower frequency of use are associated with higher QoL, regardless of gender. SCIENTIFIC SIGNIFICANCE: This is the first time QoL has been demonstrated to change over the course of CUD medication treatment. QoL is an important outcome in CUD treatment. TRIAL REGISTRATION: NCT01020019. (Am J Addict 2018;27:101-107).
RCT Entities:
BACKGROUND AND OBJECTIVE: Many patients with cannabis use disorder (CUD) do not achieve or do not have abstinence as a goal of treatment, rather they reduce their use. Assessing outcome measures as they relate to functioning and reductions in cannabis use is an important area of study. Quality of life (QoL) shows promise as one such measure. Past studies have demonstrated gender differences in QoL and CUD. We aim to assess (1) the relationship between cannabis use and QoL and (2) gender effects in an outpatient medication treatment study for CUD. METHODS: Data from an 11-weeks, double-blind, placebo-controlled trial of lofexidine and dronabinol for CUD (n = 62) was analyzed. Pearson's correlations between baseline QoL as measured with the Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form (QLES-Q-SF) and cannabis use assessed with modified timeline follow-back (TLFB) were examined. Multiple linear regression models of cannabis use on end of study QLES-Q-SF were analyzed, while adjusting for baseline QLES-Q-SF, study arm, and gender. Moderation effects with gender were also tested. RESULTS: No significant association between baseline cannabis use and QoL was found. End of study abstinence (F1,47 = 8.34, p = .006) and reduced proportion of using days (F1,47 = 9.48, p = .004) were each significantly associated with end of study QoL. Reduction in grams (F1,27 = 0.25, p = .62) was not associated with QoL at end of study. Gender was not a significant moderator. DISCUSSION AND CONCLUSIONS: Abstinence and lower frequency of use are associated with higher QoL, regardless of gender. SCIENTIFIC SIGNIFICANCE: This is the first time QoL has been demonstrated to change over the course of CUD medication treatment. QoL is an important outcome in CUD treatment. TRIAL REGISTRATION: NCT01020019. (Am J Addict 2018;27:101-107).
Authors: Frances R Levin; John J Mariani; Martina Pavlicova; Daniel Brooks; Andrew Glass; Amy Mahony; Edward V Nunes; Adam Bisaga; Elias Dakwar; Kenneth M Carpenter; Maria A Sullivan; Jean C Choi Journal: Drug Alcohol Depend Date: 2015-11-27 Impact factor: 4.492
Authors: Waguih William IsHak; James Mirocha; Scott Christensen; Fan Wu; Richard Kwock; Joseph Behjat; Sarah Pi; Araks Akopyan; Eric D Peselow; Robert M Cohen; David Elashoff Journal: Depress Anxiety Date: 2013-07-16 Impact factor: 6.505
Authors: Jose M Rubio; Mark Olfson; Laura Villegas; Gabriela Pérez-Fuentes; Shuai Wang; Carlos Blanco Journal: J Clin Psychiatry Date: 2013-05 Impact factor: 4.384
Authors: Dustin C Lee; Nicolas J Schlienz; Erica N Peters; Robert H Dworkin; Dennis C Turk; Eric C Strain; Ryan Vandrey Journal: Drug Alcohol Depend Date: 2018-11-15 Impact factor: 4.492
Authors: Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall Journal: Nat Rev Dis Primers Date: 2021-02-25 Impact factor: 52.329
Authors: Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain Journal: Drug Alcohol Depend Date: 2020-04-26 Impact factor: 4.492
Authors: Rachel L Tomko; Kevin M Gray; Marilyn A Huestis; Lindsay M Squeglia; Nathaniel L Baker; Erin A McClure Journal: Curr Addict Rep Date: 2019-11-19
Authors: Richard J Macatee; Brian J Albanese; Sarah A Okey; Kaveh Afshar; Meghan Carr; M Zachary Rosenthal; Norman B Schmidt; Jesse R Cougle Journal: J Subst Abuse Treat Date: 2020-11-05
Authors: Frances R Levin; John J Mariani; C Jean Choi; Cale Basaraba; Daniel J Brooks; Christina A Brezing; Martina Pavlicova Journal: Drug Alcohol Depend Date: 2021-05-21 Impact factor: 4.852
Authors: Brian J Sherman; Michael J Sofis; Jacob T Borodovsky; Kevin M Gray; Aimee L McRae-Clark; Alan J Budney Journal: Psychol Addict Behav Date: 2021-07-01